Regenxbio RGNX 深 沪
等待开盘 08-10 09:30:00 美东时间
10.72
-0.560
-4.96%
华盛通- 最 高11.50
- 今 开11.05
- 成交量 126.70万股
- 最 低 9.871
- 昨 收 11.28
- 总市值 46.24万
- 52周最高 16.19
- 市盈率 静 3.68
- 换手率 2937.25%
- 52周最低 5.455
- 委 比 99.22%
- 总股本 4.31万
- 历史最高 85.10
- 量 比 0.94
- 振 幅 14.44%
- 历史最低 1.10
- 每 手 1
- 风险率 2.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments
REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alongside a $100 million offering.
07-20 22:45
REGENXBIO Plans To Commence $100M Common Stock Offering
REGENXBIO Inc. (NASDAQ:RGNX) today announced that it intends to offer and sell, subject to market conditions, $100 million of its common stock in an underwritten public offering. The offering is subject to market and
07-17 04:27
Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy
FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy application.
06-22 21:23
Market-Moving News for June 22nd
SAGT: 124% | Sagtec Global CEO's 1.5M Share Acquisition And $1.56M Private Placement Coincide With FY2026 Guidance Of 35% Revenue Growth To $25.78M RGNX: 32% | 'FDA Will Reverse Rejection of Third Rare-Disease
06-22 19:11
REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval
REGENXBIO reports positive Phase 3 Duchenne trial data as RGX-202 met its primary endpoint with strong safety results.
05-15 00:03
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Earnings Scheduled For March 5, 2026
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment
REGENXBIO shares fall after the FDA issues a response letter on its Hunter syndrome gene therapy, raising trial design concerns and pushing the approval timeline.
02-10 21:51
FDA Clinical Hold Knocks REGENXBIO Stock
REGENXBIO shares sink after the FDA places a clinical hold on two gene therapy trials following a safety concern tied to abnormal tissue growth in one patient.
01-29 01:31
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
